, Tracking Stock Market Picks
Enter Symbol:
Keryx Biopharmaceuticals, Inc. (KERX) [hlAlert]

up 26.01 %

Keryx Biopharmaceuticals, Inc. (KERX) rated Outperform with price target $18 by Oppenheimer

Posted on: Friday,  Mar 20, 2015  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) on 03/20/2015. Previously Oppenheimer rated Outperform Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) on 05/17/2011.,
when the stock price was $4.92. Since then, Keryx Biopharmaceuticals, Inc. has gained 26.02% as of 01/12/2016's recent price of $6.20.
If you would have followed the previous Oppenheimer's recommendation on KERX, you would have gained 26.01% of your investment in 1701 days.

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/20/2015 8:25 AM Buy
13.80 18.00
as of 8/27/2015
1 Week down  -0.95 %
1 Month down  -38.36 %
3 Months down  -39.33 %
1 YTD down  -52.12 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/22/2014 8:25 AM Buy
13.51 22.00
5/17/2011 8:25 AM Buy
4.92 7.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy